The Company expects fourth quarter 2025 revenues of $22.5 million to $24.5 million and gross margin in the 58% to 60% range.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HBIO:
- Harvard Bioscience reports Q3 adjusted EPS 0c vs. (2c) last year
- HBIO Upcoming Earnings Report: What to Expect?
- Harvard Bioscience Granted Nasdaq Compliance Extension
- Harvard Bioscience expands distribution agreement with Fisher Scientific
- Harvard Bioscience price target lowered to $2 from $3 at Benchmark